Versavo 400mg Injection (Bevacizumab)
Prescription RequiredManufactured By
Dr. Reddy's Laboratories Ltd
Pack Of
1
Salt Composition
Bevacizumab
Storage
Refrigerate 2°C–8°C; do not freeze or shake.
- Quality-Assured Medicines
- Verified Suppliers
- Secure & Protective Packaging
- Worldwide Delivery
Safe and Secure
Your health and safety are our top priority. All our medicines are sourced from trusted suppliers, thoroughly tested, and approved for use. We follow strict quality control standards to ensure every product is safe, effective, and reliable. You can enquire knowing your wellness is in good hands.
ALL SUBSTITUTES
Bryxta 400mg Injection
Bevatas 100mg Injection
Avastin 400mg Injection
Bevarest 400mg Injection
Syndyma 400mg Injection
Abevmy 400mg Injection
Cizumab 400mg Injection
Bevacizab 400mg Injection
Bevacirel 400mg Injection
Avastin 100mg Injection
Overview
The Versavo 400mg Injection contains bevacizumab, a monoclonal antibody that binds vascular endothelial growth factor A (VEGF-A). By neutralizing VEGF-A, it suppresses tumour angiogenesis—the formation of new blood vessels that tumors use for oxygen and nutrients. Bevacizumab 400mg injection is used with chemotherapy or other systemic therapy in multiple cancers, including colorectal, nonsquamous NSCLC, renal, ovarian/fallopian/peritoneal, and cervical cancers, with indication details varying by jurisdiction. The 400 mg/16 mL vial is a supply presentation; patient dosing is weight-based in mg/kg.
Quick Product Facts
| Field | Publication wording |
|---|---|
| Brand | Versavo |
| Molecule / Combination | Bevacizumab |
| Strength / Composition | 400 mg/16 mL |
| Dosage form | IV infusion |
| Manufacturer / Marketer | Dr. Reddy's Laboratories Ltd |
| Pack / Presentation | 1 vial (16 mL) |
| Storage | Refrigerate 2°C–8°C; do not freeze or shake. |
| Prescription | Required |
Uses and Indications
Bevacizumab 400mg injection is used in metastatic colorectal cancer with fluoropyrimidine-based chemotherapy, selected advanced nonsquamous NSCLC regimens, metastatic renal cell carcinoma in selected combinations, recurrent glioblastoma under some labels, epithelial ovarian/fallopian-tube/primary-peritoneal cancer, and persistent/recurrent/metastatic cervical cancer. It is not used as a general anticancer agent for every tumor. Histology matters—serious pulmonary hemorrhage risk is one reason it is avoided in squamous NSCLC. Surgical timing, bleeding risk, uncontrolled hypertension, proteinuria, and GI perforation risk must be assessed before treatment.
How Versavo 400mg Injection Works
Bevacizumab injection binds circulating VEGF-A and prevents activation of VEGFR-1/VEGFR-2 on endothelial cells, reducing new-vessel growth and vascular permeability.
Clinical Evidence for Versavo 400mg Injection
AVF2107g: Adding bevacizumab 400mg to irinotecan/5-FU/leucovorin improved survival in metastatic colorectal cancer.
ECOG 4599: Bevacizumab 400mg injection plus carboplatin/paclitaxel improved outcomes in selected nonsquamous NSCLC patients.
GOG-0218 / ICON7: Bevacizumab-containing strategies improved progression-free outcomes in ovarian cancer populations.
Side Effects of Versavo 400mg Injection
A Versavo 400mg injection can sometimes cause unexpected physical reactions as the body adjusts to the treatment. It is always best to discuss potential responses with a doctor.
Common side effects
- High blood pressure
- Protein in urine
- Nosebleeds
- Headache
- Fatigue
- Diarrhea
Serious side effects
- Gastrointestinal perforation/fistula
- Severe hemorrhage
- Arterial thromboembolism
- Hypertensive crisis/PRES
- Nephrotic syndrome
- Impaired wound healing
- Infusion reactions
Critical Safety Warning
GI PERFORATION, BLEEDING, AND WOUND-HEALING WARNING: bevacizumab 400mg injection can cause life-threatening GI perforation, major hemorrhage, and wound-healing complications. Treatment must be withheld around major surgery according to label guidance and not restarted until adequate healing.
Versavo 400mg Injection Dosage and How To Take It
Important: Dose and regimen must be prescribed by the treating specialist. Tablet/vial strength is not necessarily the patient dose. Do not start, stop, split, combine, or substitute treatment based on website information.
| Clinical situation | Dose |
|---|---|
| Dose principle | Weight-based; common labeled doses range from 5 to 15 mg/kg IV every 2 or 3 weeks depending on cancer/regimen. |
| Colorectal example | 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks in certain regimens. |
| NSCLC example | 15 mg/kg every 3 weeks with carboplatin/paclitaxel in the classic label regimen. |
| Vial strength | 400 mg/16 mL is used to prepare the calculated dose; it is not automatically one full dose. |
Versavo 400mg Injection Missed Dose
If an infusion is missed, contact the oncology unit. Do not double or shorten the interval independently. The next dose may depend on blood pressure, proteinuria, surgery, bleeding, or toxicity.
Safety Advice for Versavo 400mg Injection
| Category | Status | Guidance |
|---|---|---|
| Surgery | Hold | Follow label-defined interruption before/after major surgery. |
| Blood pressure | Control/monitor | Treat hypertension; discontinue for crisis/PRES. |
| Kidney | Monitor | Check urine protein. |
| Pregnancy | Avoid | VEGF inhibition can harm fetal development. |
| Breastfeeding | Avoid | Follow label guidance. |
| Bleeding | High caution | Review anticoagulants and tumour bleeding risk. |
Monitoring During Versavo 400mg Injection Treatment
- Blood pressure every cycle
- Urine protein
- Bleeding/thrombosis symptoms
- Wound healing/surgical dates
- Neurologic symptoms suggestive of PRES
- Infusion reactions
Versavo 400mg Injection Fact Box
| Parameter | Verified / publication wording |
|---|---|
| Brand | Versavo |
| Generic / Combination | Bevacizumab |
| Strength | 400 mg/16 mL |
| Form | IV infusion |
| Manufacturer / Marketer | Dr. Reddy's Laboratories Ltd |
| Pack | 1 vial (16 mL) |
| Storage | Refrigerate 2°C–8°C; do not freeze or shake. |
| Major safety theme | GI PERFORATION, BLEEDING AND WOUND-HEALING WARNING |
| Prescription | Yes |
Versavo 400mg Injection Drug Interactions
| Drug / Class | Risk | What To Do |
|---|---|---|
| Anticoagulants/antiplatelets | May increase bleeding risk | Individual benefit-risk assessment and monitoring. |
| Other anti-VEGF agents | Additive toxicityq | Do not duplicate therapy. |
| Myelosuppressive chemotherapy | Combination-specific toxicity | Monitor according to regimen. |
FAQs About Versavo 400mg Injection
Does one 400 mg vial equal one dose?
No. Bevacizumab 400mg is dosed by body weight and regimen.
Why is blood pressure checked when undergoing bevacizumab 400mg injection treatment ?
Hypertension is a common anti-VEGF toxicity and can become severe.
Why should one test urine when undergoing treatment using Versavo injection?
Proteinuria can progress to nephrotic syndrome.
Why must surgery be discussed?
Bevacizumab 400mg can impair wound healing.
What abdominal symptoms are urgent?
Sudden severe abdominal pain, fever, or peritonitis can signal GI perforation.
Is bevacizumab 400mg a chemotherapy medicine?
No. It is an anti-VEGF monoclonal antibody usually combined with other cancer therapy.
Can Versavo injection be used in squamous lung cancer?
It is generally avoided because of a serious pulmonary-hemorrhage risk.
Who markets the Versavo 400mg Injection?
Current stock and prescription fulfillment can be confirmed by visiting our website. Availability may vary by location, so it is advised to first check the stock before placing an order.
References
- Current bevacizumab 400mg injection prescribing information (Avastin/reference). https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125085s340lbl.pdf.
- Hurwitz H, et al. AVF2107g. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/15175435/
- Sandler A, et al. ECOG 4599. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/17167137/
- G, joseph et al. Science Direct. Bevacizumab injection in cancer treatment. https://www.sciencedirect.com/science/article/pii/S0305737220300554
- J.pang, et al. NaturesCommunication. Efficacy of bevacizumab 400mg in cancer patients. https://www.nature.com/articles/s41467-021-21085-8.
Marketer Details
Dr. Reddy's Laboratories Ltd
Author Details
Written By:
Nonish Sharma
I am a medical content writer with a strong academic background in life sciences, holding an M.Sc. in Biotechnology... Read More
Reviewed By:
Vaibhav Shakya
Dr. Vaibhav Shakya, MD, is a Medical reviewer and medicine expert at Globans Pharma, with more than 9 years of experienc... Read More
Want to know More
Check our Editor Policy
Disclaimer
Globanspharma main goal is to ensure that its consumers get correct, authentic, and reliable information that has been examined by medical professionals. This website's content has only been created for informational purposes. However, this is not meant to replace the medical advice and treatment given by a qualified physician. The information presented herein may not cover everything about particular lab tests, medicines, and health conditions, all possible side effects, and warnings. Please discuss all your queries related to any medication and illness with your doctor. We intend to support and maintain the doctor-patient relationship, not to substitute it or take its place.
